Genmab needs to continue Phase III trial of anticancer zalutumumab
This article was originally published in Scrip
Executive Summary
Genmabwill not be able to stop the pivotal Phase III head and neck cancer trial of its experimental monoclonal antibody zalutumumab (HuMax-EGFr) early, but the Danish biotech company said it still remains optimistic that the drug will show a survival benefit in the final study analysis.